Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001819790-24-000129
Filing Date
2024-11-13
Accepted
2024-11-13 16:12:55
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tars-20240930.htm   iXBRL 10-Q 1845090
2 EX-31.1 exhibit311-93024.htm EX-31.1 9817
3 EX-31.2 exhibit312-93024.htm EX-31.2 10200
4 EX-32.1 exhibit321-93024.htm EX-32.1 6179
5 EX-32.2 exhibit322-93024.htm EX-32.2 6052
  Complete submission text file 0001819790-24-000129.txt   8413988

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20240930.xsd EX-101.SCH 49557
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20240930_cal.xml EX-101.CAL 84678
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20240930_def.xml EX-101.DEF 250875
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20240930_lab.xml EX-101.LAB 707837
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20240930_pre.xml EX-101.PRE 504030
80 EXTRACTED XBRL INSTANCE DOCUMENT tars-20240930_htm.xml XML 1087550
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39614 | Film No.: 241454349
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)